By Julie Steenhuysen, Siddhi Mahatole and Mariam Sunny May 1 (Reuters) - Moderna surpassed Wall Street estimates for ...

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...

Moderna MRNA incurred an adjusted loss (excluding litigation settlement expenses) of $1.18 per share in the first quarter of ...

Pfizer is by far the larger and better-established drugmaker. With a market cap of $156 billion, the pharmaceutical leader boasts a deep product portfolio across several therapeutic areas. Even with a ...

Moderna has opened the doors to its long-anticipated Harwell vaccine production facility in the U.K., reaffirming its commitment to Britain as its competitors take shots at the country and retreat ...

Add Yahoo as a preferred source to see more of our stories on Google. Moderna met with FDA officials after the agency initially rejected its application for a new mRNA flu vaccine. - Sarah ...

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single ...

Moderna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.

Moderna, Inc. (NASDAQ:MRNA) is one of the noteworthy S&P 500 stocks Jim Cramer highlighted. Cramer highlighted that the company is likely to remain unprofitable for “years to come,” as he stated: Next ...

Moderna shares rose 10% in premarket trading on Wednesday after the company settled a long-running legal battle over the ‌technology that made its COVID-19 vaccine possible, removing an overhang and ...

The smaller, more volatile of these two companies has higher potential for significant gains. However, that also comes with a healthy dose of risk. Choosing between these two stocks may come down to ...